HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Oncology · General and Metabolism · Diabetes Competitive Landscape

Intelligence report

Intelligence Report · ~14 min read

Oncology · General and Metabolism · Diabetes Competitive Landscape

324 findings · 940 signals · 51 insights

Type

Competitive Landscape Report

Generated

Jul 24, 2026

Confidence

Moderate Confidence · 82%

Evidence

1264 items

Sources

11

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Competitive landscape assessment for Oncology · General and Metabolism · Diabetes synthesizes 324 Competitiva findings across 940 active signals. 92 high-pressure competitive threats identified. 8 companies maintain material exposure in this therapeutic area.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. competitive

    Roche — Pipeline activity

    Roche is a regulatory competitive threat because recent agency-facing activity on Pipeline activity in Oncology · Immunotherapy may reset approval benchmarks and timeline expectations for Merck.

    View detail
  2. competitive

    Pfizer — QTERN

    Pfizer is a regulatory competitive threat because recent agency-facing activity on QTERN in Diabetes · SGLT2 Inhibitor / DPP-4 Inhibitor may reset approval benchmarks and timeline expectations for AstraZeneca.

    View detail
  3. competitive

    AstraZeneca — Verzenio

    AstraZeneca is a regulatory competitive threat because recent agency-facing activity on Verzenio in Oncology · CDK4/6 Inhibitor may reset approval benchmarks and timeline expectations for Lilly.

    View detail
  4. competitive

    Pfizer — Pipeline activity

    Pfizer is a direct competitive threat because it has a Phase III program in Oncology · KRAS G12C NSCLC (Pipeline activity) and could narrow Roche's development lead.

    View detail
  5. competitive

    Pfizer — Pipeline activity

    Pfizer is a direct competitive threat because it has a Phase III program in Oncology · KRAS G12C NSCLC (Pipeline activity) and could narrow Roche's development lead.

    View detail
  6. competitive

    AstraZeneca — GLEEVEC

    AstraZeneca is a regulatory competitive threat because recent agency-facing activity on GLEEVEC in Oncology · Tyrosine Kinase Inhibitor may reset approval benchmarks and timeline expectations for Novartis.

    View detail
  7. competitive

    Lilly — GLEEVEC

    Lilly is a regulatory competitive threat because recent agency-facing activity on GLEEVEC in Oncology · Tyrosine Kinase Inhibitor may reset approval benchmarks and timeline expectations for Novartis.

    View detail
  8. competitive

    Pfizer — STEGLUJAN

    Pfizer is a direct competitive threat because it is already approved in Diabetes · SGLT2 Inhibitor / DPP-4 Inhibitor (STEGLUJAN) and could narrow Merck's development lead.

    View detail
  9. competitive

    Pfizer — STEGLATRO

    Pfizer is a regulatory competitive threat because recent agency-facing activity on STEGLATRO in Diabetes · SGLT2 Inhibitor may reset approval benchmarks and timeline expectations for Merck.

    View detail
  10. competitive

    Pfizer — Farxiga

    Pfizer is a regulatory competitive threat because recent agency-facing activity on Farxiga in Diabetes · SGLT2 Inhibitor may reset approval benchmarks and timeline expectations for AstraZeneca.

    View detail
  11. competitive

    Roche — pembrolizumab

    Roche is a direct competitive threat because it has a Phase III program in Oncology · Cutaneous Angiosarcoma (pembrolizumab) and could narrow Merck's development lead.

    View detail
  12. competitive

    Roche — pembrolizumab

    Roche is a direct competitive threat because it has a Phase III program in Oncology · Cutaneous Angiosarcoma (pembrolizumab) and could narrow Merck's development lead.

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Monitor 92 high-pressure competitive programs for portfolio displacement risk. Cross-reference 51 executive insights for synthesized strategic assessment. Leading competitive pressure: High across top-linked programs.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Roche — Pipeline activity

    85%

    Roche is a regulatory competitive threat because recent agency-facing activity on Pipeline activity in Oncology · Immunotherapy may reset approval benchmarks and timeline expectations for Merck.

    Source: Humanexa Signals

    View evidence

  • Pfizer — QTERN

    95%

    Pfizer is a regulatory competitive threat because recent agency-facing activity on QTERN in Diabetes · SGLT2 Inhibitor / DPP-4 Inhibitor may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Pfizer

    View evidence

  • AstraZeneca — Verzenio

    95%

    AstraZeneca is a regulatory competitive threat because recent agency-facing activity on Verzenio in Oncology · CDK4/6 Inhibitor may reset approval benchmarks and timeline expectations for Lilly.

    Source: Humanexa Signals

    View evidence

  • Pfizer — Pipeline activity

    63%

    Pfizer is a direct competitive threat because it has a Phase III program in Oncology · KRAS G12C NSCLC (Pipeline activity) and could narrow Roche's development lead.

    Source: Pfizer

    View evidence

  • Pfizer — Pipeline activity

    55%

    Pfizer is a direct competitive threat because it has a Phase III program in Oncology · KRAS G12C NSCLC (Pipeline activity) and could narrow Roche's development lead.

    Source: Humanexa Signals

    View evidence

  • AstraZeneca — GLEEVEC

    80%

    AstraZeneca is a regulatory competitive threat because recent agency-facing activity on GLEEVEC in Oncology · Tyrosine Kinase Inhibitor may reset approval benchmarks and timeline expectations for Novartis.

    Source: Humanexa Signals

    View evidence

  • Lilly — GLEEVEC

    95%

    Lilly is a regulatory competitive threat because recent agency-facing activity on GLEEVEC in Oncology · Tyrosine Kinase Inhibitor may reset approval benchmarks and timeline expectations for Novartis.

    Source: Humanexa Signals

    View evidence

  • Pfizer — STEGLUJAN

    79%

    Pfizer is a direct competitive threat because it is already approved in Diabetes · SGLT2 Inhibitor / DPP-4 Inhibitor (STEGLUJAN) and could narrow Merck's development lead.

    Source: Pfizer

    View evidence

  • Pfizer — STEGLATRO

    90%

    Pfizer is a regulatory competitive threat because recent agency-facing activity on STEGLATRO in Diabetes · SGLT2 Inhibitor may reset approval benchmarks and timeline expectations for Merck.

    Source: Pfizer

    View evidence

  • Pfizer — Farxiga

    95%

    Pfizer is a regulatory competitive threat because recent agency-facing activity on Farxiga in Diabetes · SGLT2 Inhibitor may reset approval benchmarks and timeline expectations for AstraZeneca.

    Source: Pfizer

    View evidence

  • Roche — pembrolizumab

    77%

    Roche is a direct competitive threat because it has a Phase III program in Oncology · Cutaneous Angiosarcoma (pembrolizumab) and could narrow Merck's development lead.

    Source: Roche

    View evidence

  • Roche — pembrolizumab

    77%

    Roche is a direct competitive threat because it has a Phase III program in Oncology · Cutaneous Angiosarcoma (pembrolizumab) and could narrow Merck's development lead.

    Source: Roche

    View evidence

  • Pfizer — AFINITOR

    95%

    Pfizer is a regulatory competitive threat because recent agency-facing activity on AFINITOR in Oncology · mTOR Inhibitor may reset approval benchmarks and timeline expectations for Novartis.

    Source: Pfizer

    View evidence

  • Lilly — AFINITOR

    95%

    Lilly is a regulatory competitive threat because recent agency-facing activity on AFINITOR in Oncology · mTOR Inhibitor may reset approval benchmarks and timeline expectations for Novartis.

    Source: Humanexa Signals

    View evidence

  • Merck — GDC-7035

    81%

    Merck is a direct competitive threat because it has a Phase III program in Oncology · KRAS Inhibitor (GDC-7035) and could narrow Roche's development lead.

    Source: Merck

    View evidence

  • Roche — Pipeline activity

    86%

    Roche is a direct competitive threat because it has a Phase III program in Oncology · Lung Cancer (Pipeline activity) and could narrow AstraZeneca's development lead.

    Source: Roche

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment

    Regulatory Approval

  • Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial

    Trial Update

  • Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial

    Trial Update

  • Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma

    Regulatory Approval

  • FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer

    Regulatory Approval

  • Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer

    Regulatory Approval

  • Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

    Trial Update

  • FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

    Regulatory Approval

Insights

  • Roche's Regulatory Momentum Enhances Competitive Position in Oncology and Autoimmunity

    Oncology · Various, Autoimmunity · Various

  • Lilly's Revenue Surge Signals Competitive Shift in GLP-1 Market

    Diabetes · GLP-1

  • Emerging Competitive Landscape in Oncology: CDK7 Inhibition and EGFR Resistance Therapies

    Oncology · CDK7 Inhibition

  • NCI's New Tissue Repository: A Catalyst for Pediatric Oncology Innovation

    Oncology · Pediatric Cancers

  • Clinical Trial on Autoimmune Thyroiditis May Transform Thyroid Cancer Management

    Oncology · Thyroid Cancer

  • Emerging Competitive Threat in Continuous Glucose Monitoring Market from SAVA Technologies

    Diabetes · Continuous Glucose Monitoring

  • Optimizing Chemotherapy Protocols through Hyperthermia-Enhanced Doxorubicin Delivery

    Oncology · Chemotherapy

  • Insulet's Omnipod Recall: Strategic Risks and Competitive Dynamics in Insulin Delivery

    Diabetes · Insulin Delivery

Companies

  • Roche

    212 signals

  • Pfizer

    140 signals

  • Merck

    132 signals

  • AstraZeneca

    127 signals

  • Eli Lilly

    78 signals

  • Novartis

    38 signals

  • Bristol Myers Squibb

    38 signals

  • Janssen

    36 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.